Legal and financial questions of Pfizer-Novo-Metsera
Shareholder Primacy
00:00
Is Novo’s New Bid Truly Likely to Close?
Ann and Mike analyze MetSera’s claim that regulator discussions changed the antitrust calculus and whether that suffices.
Play episode from 20:53
Transcript
